Published Date: 3-Feb-2021
Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support
According to a new report LAMEA Castrate-Resistant Prostate Cancer Market, published by KBV research, the LAMEA Castrate-resistant Prostate Cancer Market would witness market growth of 9.1% CAGR during the forecast period (2020-2026).
The Brazil market dominated the LAMEA Castrate-resistant Prostate Cancer Market by Country in 2019, thereby, achieving a market value of $32.6 million by 2026. The Argentina market would witness a CAGR of 10% during (2020 - 2026). Additionally, The UAE market is exhibiting a CAGR of 8.5% during (2020 - 2026).
The Hormonal Therapy market dominated the Saudi Arabia Castrate-resistant Prostate Cancer Market by Therapy in 2019, growing at a CAGR of 8.9 % during the forecast period. The Immunotherapy market is estimated to grow at a CAGR of 6.8% during (2020 - 2026). Additionally, The Chemotherapy market would showcase highest CAGR of 11.6% during (2020 - 2026).
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the mentioned countries. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Sanofi S.A., Johnson and Johnson, Pfizer, Inc., Bayer AG, Abbott Laboratories, GlaxoSmithKline PLC (GSK), Northwest Biotherapeutics, Inc., Active Biotech AB, Astellas Pharma, Inc. and Dendreon Pharmaceuticals LLC (Sanpower Group Co., Ltd.)
Unique Offerings from KBV Research